Genentech, Inc. (Jobs) Stock Down After Avastin Fails, Sales Stall

March 23 (Bloomberg) -- Shares of Genentech Inc., the world's second-biggest biotechnology company, fell the most in two years after first-quarter sales stalled and researchers halted a study of the cancer drug Avastin.

>>> Discuss This Story